Fig. 4
From: Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia
Wogonin exhibits anti-tumor effects and exerted lower toxicity in vivo. In total, KU-812 cells (6 × 106 cells/mouse) were subcutaneously inoculated into NOD/SCID mice. The mice were randomized into 6 groups (6 mice per group), and treated with wogonin (80 mg/kg), Imatinib (200 mg/kg) and 0.9% normal saline for 2 weeks. a The tumor volume was measured and calculated every other day. Data represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, compared with control group. b The resulting tumors excised from the animals after treatment. c The tumor weights in three groups were compared. Quantification of the data shown. Data represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, compared with control group. d Effect of wogonin on expression of Ki67 in KU-812 xenografts (Original magnification × 600). e–f Wogonin inhibits the splenomegaly of KU-812-bearing NOD/SCID mice. The typical photos of the spleen. Effect of wogonin on the weight of spleen in KU-812 cells-bearing NOD/SCID mice. Each data point represents the mean ± SD of four animals for each group. **p < 0.01, ***p < 0.001, compared with control group. g Effect of wogonin on expression of huCD45+ in spleen of KU-812-bearing NOD/SCID mice. Spleen samples from three mice of each group (Original magnification × 600)